4551.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 09:15):

Stats
Объем за сегодня	48 200.00
Средний объем	31 351.00
Рыночная капитализация	108.35B
EPS	¥0 ( 2024-04-25 )
Last Dividend	¥50.00 ( 2023-06-29 )
Next Dividend	¥0 ( N/A )
P/E	26.32
ATR14	¥5.18 (0.13%)

Объем Корреляция

Длинно: 0.15 (neutral)

Кратко: 0.40 (neutral)

Signal:(54.642) Neutral

Torii Pharmaceutical Co., Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Torii Pharmaceutical Co., Корреляция - Валюта/Сырье

0.54
( weak )

0.57
( weak )

-0.53
( weak negative )

0.37
( neutral )

0.35
( neutral )

-0.28
( neutral )

Torii Pharmaceutical Co., Финансовые показатели

Annual	2023
Выручка:	¥54.64B
Валовая прибыль:	¥24.57B (44.97 %)
EPS:	¥146.57

FY	2023
Выручка:	¥54.64B
Валовая прибыль:	¥24.57B (44.97 %)
EPS:	¥146.57

FY	2022
Выручка:	¥48.89B
Валовая прибыль:	¥23.38B (47.81 %)
EPS:	¥140.38

FY	2021
Выручка:	¥46.99B
Валовая прибыль:	¥24.34B (51.80 %)
EPS:	¥32.16

Financial Reports:

No articles found.

Torii Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥76.00 (N/A)	¥0 (N/A)	¥50.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Torii Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.90 - good (89.04%) | Divividend Growth Potential Score: 4.42 - Stable (11.60%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥2.00	2001-03-27
Last Dividend	¥50.00	2023-06-29
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	¥907.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.47	--
Div. Sustainability Score	8.90
Div.Growth Potential Score	4.42
Div. Directional Score	6.66	--

Next Divdend (Est)
(2024-09-25)

¥0 Estimate 3.76 %

Dividend Stability

0.30 Poor

Dividend Score

3.47

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8349.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7732.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
6908.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
6272.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4980.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4198.T	Ex Dividend Knight	2024-05-30	Annually	0.00%
3395.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2477.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
9413.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8077.T	Ex Dividend Knight	2023-10-30	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0754	1.500	8.49	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0309	1.200	8.97	10.00	[0 - 0.3]
returnOnEquityTTM	0.0347	1.500	-0.725	-1.088	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	7.05	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.09	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.77	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00183	-1.500	9.97	-10.00	[0 - 0.6]
interestCoverageTTM	-152.61	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00203	-1.500	9.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.454	1.000	5.77	5.77	[0.2 - 0.8]
operatingProfitMarginTTM	0.0922	1.000	-0.157	-0.157	[0.1 - 0.6]
cashFlowToDebtRatioTTM	3.76	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.409	0.800	-0.603	-0.483	[0.5 - 2]
Total Score				8.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	26.31	1.000	7.44	0	[1 - 100]
returnOnEquityTTM	0.0347	2.50	-0.466	-1.088	[0.1 - 1.5]
freeCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.11	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	32.66	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.575	1.500	9.50	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0168	1.000	-2.08	0	[0.1 - 0.5]
Total Score				4.42

Torii Pharmaceutical Co.,

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.